Recent Press Releases

New England Journal of Medicine publishes positive results from COMBI-v study of trametinib (Mekinist™) and dabrafenib (Tafinlar™) combination

New England Journal of Medicine publishes positive results from COMBI-v study of trametinib (Mekinist™) and dabrafenib (Tafinlar™) combination Results published today in the New England...

BLOOD CLOT AND HEART ATTACK RISK AFTER CORONARY STENT TREATMENT REDUCED WITH CONTINUATION OF DUAL ANTIPLATELET THERAPY BEYOND ONE YEAR IN DAPT STUDY FINDINGS

BLOOD CLOT AND HEART ATTACK RISK AFTER CORONARY STENT TREATMENT REDUCED WITH CONTINUATION OF DUAL ANTIPLATELET THERAPY BEYOND ONE YEAR IN DAPT STUDY FINDINGS Results Presented at the American Heart...

FDA approves Roche's Avastin plus chemotherapy to treat women with platinum-resistant recurrent ovarian cancer

FDA approves Roche's Avastin plus chemotherapy to treat women with platinum-resistant recurrent ovarian cancer Avastin plus chemotherapy reduced the risk of the disease worsening by 62 percent...

Amgen To Present At The Jefferies Global Healthcare Conference

THOUSAND OAKS, Calif., Nov.

FDA Approves Genentech's Avastin (bevacizumab) Plus Chemotherapy to Treat Women with Platinum-Resistant Recurrent Ovarian Cancer

-- Avastin Plus Chemotherapy Reduced the Risk of the Disease Worsening by 62 Percent Compared to Chemotherapy Alone in a Phase III Study - SOUTH SAN FRANCISCO, Calif.--()--Genentech, a...

Valeant Pharmaceuticals Completes Renovation Of U.S. Headquarters In New Jersey

Expansion of its U.S. headquarters solidifies commitment to grow jobs and support the local economy LAVAL, Quebec, Nov. 13, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (VRX)...

Bristol-Myers Squibb to Construct a New Large-Scale Biologics Manufacturing Facility in Cruiserath, Ireland

State-of-the-art facility will produce multiple therapies for the company's growing biologics portfolio Significant investment builds on 50 years of company's manufacturing history in...

Families and Flu: What You Need to Know Now

- Peak Flu Activity Usually Occurs Between December - February

PHILADELPHIA, Nov.

AstraZeneca Announces Initiation of Development Program for BRILINTA (ticagrelor) Reversal Agent

Updates on BRILINTA (ticagrelor) tablets development program and data from cardiovascular portfolio to be presented at American Heart Association (AHA) Scientific Sessions 2014 WILMINGTON, Del.--(...

Mallinckrodt plc Responds to FDA's Expected Reclassification of Methylphenidate ER

DUBLIN--(BUSINESS WIRE)-- Mallinckrodt plc (MNK) has been informed by the U.S. Food and Drug Administration (FDA) that the agency has reason to believe that the company's methylphenidate...

Merck Reports Strong Top-Line Growth in Q3

Merck Reports Strong Top-Line Growth in Q3 Sales increase by 9.3% in Q3, driven by the AZ acquisition and solid organic growth in all businesses All regions on a growth course, Emerging Markets fuel...

Malaria No More Reaches Power Of One Campaign Goal for Treatments In Zambia

Campaign Secures 3 Million Life-Saving Malaria Treatments in Advance of Three Year Goal Using Tech Tools to Mobilize Global Public

NEW YO

Amgen To Highlight New Data For Investigational Cholesterol-Lowering Medication Evolocumab

Thirteen Presentations Include New Analyses of PCSK9 Inhibitor at Upcoming American Heart Association Scientific Sessions

THOUSAND OAKS,

Roche Teams Up with LabCentral to Support Biotech Startups

- World's largest biotech company providing funding as well as instrumentation for accelerating genetic and proteomic workflows

CAMBRIDGE

The Amgen Foundation Expands Amgen Scholars Program to 17 Top Educational Institutions Worldwide

Foundation's Commitment to Science, Technology, Engineering and Math (STEM) Education Surpasses $100 Million Milestone

THOUSAND OAKS, Cal

Janssen Highlights its Hepatitis C Clinical Development Program in Advance of 2014 American Association for the Study of Liver Diseases (AASLD) Annual Meeting

Studies focused on patients where there is a high unmet need today or anticipated in the near future BOSTON (November 7, 2014) - Janssen R&D Ireland (Janssen) highlights its hepatitis C (HCV)...

GSK announces EU regulatory submission seeking additional indication for eltrombopag (Revolade™)

GSK announces EU regulatory submission seeking additional indication for eltrombopag (Revolade™) 12 November 2014 Issued: London, UK GSK today announced the submission to the European Medicines...

GSK Survey Points to Rise of COPD in US

Study reveals increased prevalence and considerable burden of COPD

RESEARCH TRIANGLE PARK, N.C., Nov.